NIAC has been involved in assessing the evidence and liaising with international stakeholders on new vaccines as they are being developed against COVID-19 to inform a national immunisation programme. The rollout of the vaccine is being implemented by the Department of Health and the Health Service Executive.
Following the recommendation for use of the Pfizer-BioNTech vaccine, Comirnaty®, COVID-19 Vaccine - Moderna, COVID-19 Vaccine - Astra Zeneca (now known as Vaxzevria®) and COVID-19 Vaccine Janssen® by the European Medicines Agency (EMA) and authorisation for use by the European Commission, NIAC has developed guidance for their use in Ireland which is contained in the Immunisation Guidelines for Ireland. These guidelines are continuously updated and will include guidance on new vaccines as they are approved for use in Ireland.
Priority Groups for vaccination
NIAC also developed Provisional Vaccine Allocation Groups to receive the vaccines as they become available. These groups were considered and adopted by the Government. The priority group listing is undergoing a rolling review, considering new evidence, epidemiology and vaccine supplies. Any update to the recommended priority groups will be notified to the Department of Health for consideration.
Updated 05 May 2021
Published 15 March 2021